KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

TherapeuticsMD (TXMD) Income towards Parent Company (2016 - 2026)

TherapeuticsMD filings provide 17 years of Income towards Parent Company readings, the most recent being -$8000.0 for Q1 2026.

  • On a quarterly basis, Income towards Parent Company rose 52.94% to -$8000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $93000.0, a 138.46% increase, with the full-year FY2025 number at $84000.0, down 35.88% from a year prior.
  • Income towards Parent Company hit -$8000.0 in Q1 2026 for TherapeuticsMD, down from -$7000.0 in the prior quarter.
  • In the past five years, Income towards Parent Company ranged from a high of $127.2 million in Q2 2022 to a low of -$31.1 million in Q1 2022.
  • Median Income towards Parent Company over the past 5 years was -$7500.0 (2025), compared with a mean of $6.8 million.
  • Biggest five-year swings in Income towards Parent Company: surged 398.12% in 2022 and later plummeted 122.67% in 2025.
  • TherapeuticsMD's Income towards Parent Company stood at $29.2 million in 2022, then crashed by 97.75% to $658000.0 in 2023, then tumbled by 79.03% to $138000.0 in 2024, then crashed by 105.07% to -$7000.0 in 2025, then dropped by 14.29% to -$8000.0 in 2026.
  • The last three reported values for Income towards Parent Company were -$8000.0 (Q1 2026), -$7000.0 (Q4 2025), and $102000.0 (Q3 2025) per Business Quant data.